| Released | Contributor | Author | Title | Pages | Price |
| 29-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Eli Lilly has a current Overall Rating of C (Neutral). | 7 |
$25 |
| 29-Nov-2009 | Freedonia Group Inc, The | The Freedonia Group | Freedonia Focus on Cancer Therapies | 23 |
$500 |
| 27-Nov-2009 | Validea |
N/A
| Validea Guru Analysis Report for LLY. Analysis using Validea's interpretation of the published quantitative strategies of well-known Wall Street experts including Peter Lynch, Warren Buffett, Ben Graham and Ken Fisher, among others. | 0 |
$18 |
| 26-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for DRUGS | 18 |
$49 |
| 26-Nov-2009 | Stock Traders Daily | Thomas H. Kee Jr. | Trading Report for (LLY). A detailed Technical Analysis + Trading Plans for Day Trading, Swing Trading, and Long Term proactive investments in (LLY). | 5 |
$18 |
| 26-Nov-2009 | New Constructs, LLC |
N/A
| LLY: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 |
| 26-Nov-2009 | Pechala's Reports | Lubomir Pechala | ELI LILLY AND COMPANY (LLY=US) - REPORT FOR ACTIVE TRADERS | 4 |
$25 |
| 24-Nov-2009 | Jefferson Research |
N/A
| Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of LILLY (ELI) & CO including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation. | 3 |
$20 |
| 23-Nov-2009 | PriceTarget Research, Inc. |
N/A
| NYSE US 100 Intelligence Monitor: overall outlook NEUTRAL - 14 new Leaders; 17 new Laggards. | 46 |
$40 |
| 23-Nov-2009 | Reuters Investment Profile |
N/A
| Eli Lilly and Co: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. | 12 |
$20 |
1.48% Nasdaq 
Research Reports
